$Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH$ 0:03:16

Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH

Name: Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Uploaded: 2019-12-12T11:07:53
Duration: 3 min 16 s
Description: John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL).

ash

5 months

29 Views

Share Report Add to 0 0

Share Video (Iframe):

<iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://www.oncologytube.com/videoEmbed/38288/venetoclax-rituximab-venr-in-relapsed-refractory-r-r-cll-ash19-ash?channelName=ash" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe>

Share Video (Object):

<object width="640" height="360"><param name="movie" value="https://www.oncologytube.com/videoEmbed/38288/venetoclax-rituximab-venr-in-relapsed-refractory-r-r-cll-ash19-ash?channelName=ash"></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://www.oncologytube.com/videoEmbed/38288/venetoclax-rituximab-venr-in-relapsed-refractory-r-r-cll-ash19-ash?channelName=ash" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object>

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Chronic Lymphocytic Leukemia

Description:

John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL).